US EditionPublished • loading... • Updated
WHO Issues First Guidelines for GLP-1 Obesity Treatments
WHO conditionally recommends GLP-1 drugs for obesity treatment but warns fewer than 10% of eligible people will access them due to cost and health system limits.
- On Monday, the World Health Organization recommended GLP-1 drugs as a tool to manage obesity in adults, publishing guidance in JAMA defining long-term use as six months or more.
- Regulatory approvals, including by the Food and Drug Administration, preceded the guidance drafted by a committee of obesity, pharmacology and public-health experts at the request of WHO member states amid debate in recent years.
- GLP-1 drugs work by mimicking a hormone that signals fullness and reduce appetite to help people lose weight, while more than 890 million adults worldwide are obese and obesity causes 3.7 million deaths annually.
- The recommendation is conditional, the WHO said, as benefits likely outweigh downsides but more long-term safety and efficacy data, plus lower prices, are needed to address access and pricing concerns.
- In the U.S., one in eight adults report currently taking a GLP-1 drug amid the societal shift in obesity framing and WHO urging public-health coordination.
Insights by Ground AI
Podcasts & Opinions
171 Articles
171 Articles
Ghebreyesus argues that new guidelines "recognize that obesity is a chronic disease that can be treated with comprehensive care and life-long".
·Portugal
Read Full Article
GLP-1-type consumer drugs can be used in long-term therapy, but access remains a problem.
The WHO has published its first guideline on the use of so-called weight loss shots against obesity.
·Germany
Read Full Article
WHO backs Ozempic-type drugs for treating obesity
WHO guidelines said GLP-1 medications such as Ozempic or Wegovy could be used by adults as part of a comprehensive approach to obesity treatment. Photo: Getty Images The World Health Organization has released its first guidelines on the Ozempic-type drugs, conditionally recommending their use for long-term treatment of obesity.
·Otago, New Zealand
Read Full ArticleCoverage Details
Total News Sources171
Leaning Left26Leaning Right11Center33Last UpdatedBias Distribution47% Center
Bias Distribution
- 47% of the sources are Center
47% Center
L 37%
C 47%
R 16%
Factuality
To view factuality data please Upgrade to Premium
